Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort

Ophthalmology

Volumn 121, Issue 3, 2014, Pages 676-681

  Gillies, Mark C ^a   Walton, Richard J ^a   Arnold, Jennifer J ^b   McAllister, Ian L ^c   Simpson, Judy M ^d   Hunyor, Alex P ^e   Guymer, Robyn ^f   Essex, Rohan W ^g   Morlet, Nigel ^c   Barthelmes, Daniel ^a,h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Marsden Eye Specialists   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Retina Associates   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84896713265     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.09.050     Document Type: Article

References (22)

1. R. Temple Enrichment of clinical study populations Clin Pharmacol Ther 88 2010 774 778
2. P.J. Rosenfeld, D.M. Brown, and J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
3. D.M. Brown, P.K. Kaiser, and M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
4. M. Biarnes, J. Mones, J.R. Villalbi, and L. Arias As-needed treatment with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration Eur J Ophthalmol 21 2011 282 289
5. H. Dadgostar, A.A. Ventura, and J.Y. Chung et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration Ophthalmology 116 2009 1740 1747
6. A. Kumar, J.N. Sahni, and A.N. Stangos et al. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy Br J Ophthalmol 95 2011 530 533
7. S.Y. Cohen, L. Dubois, and R. Tadayoni et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting Am J Ophthalmol 148 2009 409 413
8. M. Kruger Falk, H. Kemp, and T.L. Sorensen Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment Am J Ophthalmol 155 2013 89 95
9. B. Heimes, A. Lommatzsch, and M. Zeimer et al. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme Graefes Arch Clin Exp Ophthalmol 249 2011 639 644
10. L. Hjelmqvist, C. Lindberg, and P. Kanulf et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study J Ophthalmol [serial online] 2011 2011 405724 Available at http://www.hindawi.com/journals/ jop/2011/405724/ Accessed September 8, 2013
11. Y. Tao, T. Libondi, and J.B. Jonas Long-term follow-up after multiple intravitreal bevacizumab injections for exudative age-related macular degeneration J Ocul Pharmacol Ther 26 2010 79 83
12. G.S. Ying, J. Huang, and M.G. Maguire Comparison of Age-related Macular Degeneration Treatments Trials Research Group Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 2013 122 129
13. D.M. Brown, L. Tuomi, H. Shapiro PIER Study Group Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration Retina 33 2013 23 34
14. Gillies MC, Walton R, Liong J, et al. Efficient capture of high quality data on outcomes of treatment for macular diseases: the Fight Retinal Blindness! Project. Retina 2013 Jul 3. [Epub ahead of print]
15. R.G. Newcombe, and G.R. Duff Eyes or patients? Traps for the unwary in the statistical analysis of ophthalmological studies Br J Ophthalmol 71 1987 645 646
16. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group D.F. Martin, M.G. Maguire, and S.L. Fine et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
17. M. Menghini, B. Kloeckener-Gruissem, and J. Fleischhauer et al. Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration PLoS One [serial online] 7 2012 e42014 Available at http://www.plosone.org/article/ info%3Adoi%2F10.1371%2Fjournal.pone.0042014 Accessed September 8, 2013
18. G. Querques, S. Azrya, and D. Martinelli et al. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting Br J Ophthalmol 94 2010 292 296
19. M.C. Gillies, R. Walton, and J.M. Simpson Fight Retinal Blindness! Project Investigators Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naïve eyes Invest Ophthalmol Vis Sci 54 2013 5754 5760
20. D.S. Boyer, A.N. Antoszyk, and C.C. Awh MARINA Study Group Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration Ophthalmology 114 2007 246 252
21. P.K. Kaiser, D.M. Brown, and K. Zhang et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results Am J Ophthalmol 144 2007 850 857
22. J.P. Ioannidis, A.B. Haidich, and M. Pappa et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies JAMA 286 2001 821 830